Teva   2Q Revenues: $4.9 billion (-1%) 2Q Loss: $456 million (earnings were $859 million 2Q12) YTD Revenues: $9.8 billion (-3%) YTD Earnings: $170 million (earnings were $1.7 billion YTD12) Comments: Generic revenues in the quarter (including API sales of $181 million) were down 8% to $2.6 billion. Specialty revenues were $2.1 billion, up 5%. U.S. sales in the quarter were $2.5 billion (51% of revenues), up 2%, driven primarily by Copaxone sales (+9% to $1.1 billion), offset by lower generic...